Company news
Tg Therapeutics, Inc. (NASDAQ:TGTX) news
Tg Therapeutics, Inc. news releases on 6ix. Latest, Aug 6, 2020: TG Therapeutics to Host Conference Call on Second Quarter 2020 Financial Results and Business…
Press releases — page 5
TG Therapeutics to Host Conference Call on Second Quarter 2020 Financial Results and Business Update
August 5, 2020
TG Therapeutics Announces Publication in Blood Advances Describing Unique Immunomodulatory Effects on CLL T cells by Umbralisib
July 7, 2020
TG Therapeutics Announces Preclinical Data Presentation at the 2020 American Association for Cancer Research Annual Meeting
June 21, 2020
TG Therapeutics Completes Rolling Submission of New Drug Application to the U.S. Food and Drug Administration for Umbralisib as a Treatment for Patients with Previously Treated Marginal Zone Lymphoma or Follicular Lymphoma
June 16, 2020
TG Therapeutics to Present at the Raymond James 2020 Human Health Innovation Conference
June 15, 2020
TG Therapeutics Announces Data Presentations at the 25th European Hematology Association (EHA) Annual Congress
June 11, 2020
TG Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare Conference
June 8, 2020
TG Therapeutics to Present at the Jefferies 2020 Healthcare Conference
June 1, 2020
TG Therapeutics Announces Final Results of the GENUINE Phase 3 Study Evaluating Ublituximab plus Ibrutinib in Previously Treated High-Risk Chronic Lymphocytic Leukemia at the 56th American Society of Clinical Oncology Annual Meeting
May 28, 2020
TG Therapeutics Announces Preclinical Data Presentation at the Upcoming American Association for Cancer Research Annual Meeting
May 14, 2020
TG Therapeutics Provides Business Update and Reports First Quarter 2020 Financial Results
May 10, 2020
TG Therapeutics Strengthens Executive Team with the Addition of Owen A. O’Connor, MD, PhD, as Chief Scientific Officer
May 7, 2020
TG Therapeutics Raises Approximately $60 Million in Gross Proceeds Through its At-the-Market Facility
May 5, 2020
TG Therapeutics Announces Positive Topline Results from the UNITY-CLL Phase 3 Study Evaluating the Combination of Umbralisib and Ublituximab (U2) for the Treatment of Patients with Chronic Lymphocytic Leukemia
May 4, 2020
TG Therapeutics Announces Publication of Ublituximab Phase 2 Clinical Trial Results in Multiple Sclerosis Journal
April 30, 2020
TG Therapeutics Bolsters Board of Directors with the Appointment of Sagar Lonial, MD
April 28, 2020
TG Therapeutics Announces Data Presentations at the Upcoming American Academy of Neurology 72nd Annual Meeting
March 8, 2020
TG Therapeutics Receives Orphan Drug Designation for Umbralisib from the U.S. Food and Drug Administration for the Treatment of Follicular Lymphoma
March 4, 2020
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2019 Financial Results
March 2, 2020
TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2019 Financial Results and Business Update
February 27, 2020
TG Therapeutics Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for Umbralisib as a Treatment for Patients with Previously Treated Marginal Zone Lymphoma or Follicular Lymphoma
January 15, 2020
TG Therapeutics Announces $50.0 Million Registered Direct Public Offering of Common Stock to a Single Institutional Investor
December 22, 2019
TG Therapeutics Announces Phase I Data Presentation for TG-1701, a Once-Daily BTK Inhibitor, as a Single Agent and in Triple Combination with Ublituximab and Umbralisib (U2), at the 61st American Society of Hematology Annual Meeting and Exposition
December 8, 2019
TG Therapeutics Announces Oral Presentation of Umbralisib, Ublituximab and Venetoclax Triple Combination Phase I/II Data in Relapsed/Refractory CLL at the 61st American Society of Hematology Annual Meeting and Exposition
December 7, 2019
TG Therapeutics Provides Business Update and Reports Third Quarter 2019 Financial Results
November 11, 2019
TG Therapeutics to Host Conference Call on Third Quarter 2019 Financial Results and Business Update
November 7, 2019
TG Therapeutics Announces Triple Combination Data Presentations at the Upcoming 61st American Society of Hematology Annual Meeting and Exposition
November 5, 2019
TG Therapeutics Announces Positive Results from the UNITY-NHL Phase 2b Pivotal Trial Evaluating Umbralisib Monotherapy in Patients with Relapsed/Refractory Follicular Lymphoma
October 27, 2019
TG Therapeutics Announces Publication of Clinical Data from the Phase I/Ib Combination Trial of Ublituximab and Umbralisib (“U2”) in Blood
September 29, 2019
TG Therapeutics Announces Data Presentations at the XVIII International Workshop on Chronic Lymphocytic Leukemia (iwCLL)
September 22, 2019
TG Therapeutics Presents Data for Ublituximab at the 35th Annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
September 11, 2019
TG Therapeutics Receives Orphan Drug Designation for Umbralisib from the U.S. Food and Drug Administration for the Treatment of Marginal Zone Lymphoma
April 14, 2019
TG Therapeutics Reports Positive Interim Data from UNITY-NHL Phase 2b Trial Evaluating Umbralisib Monotherapy in Patients with Marginal Zone Lymphoma at the 2019 AACR Annual Meeting
March 31, 2019